BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31639796)

  • 1. Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms.
    Lim KHJ; Raja H; D'Arienzo P; Barriuso J; McNamara MG; Hubner RA; Mansoor W; Valle JW; Lamarca A
    Neuroendocrinology; 2020; 110(7-8):688-696. PubMed ID: 31639796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis.
    Garcia-Torralba E; Spada F; Lim KHJ; Jacobs T; Barriuso J; Mansoor W; McNamara MG; Hubner RA; Manoharan P; Fazio N; Valle JW; Lamarca A
    Cancer Treat Rev; 2021 Mar; 94():102168. PubMed ID: 33730627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.
    Kapacee ZA; Allison J; Dawod M; Wang X; Frizziero M; Chakrabarty B; Manoharan P; McBain C; Mansoor W; Lamarca A; Hubner R; Valle JW; McNamara MG
    Curr Oncol; 2022 Jul; 29(7):5110-5125. PubMed ID: 35877265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.
    Alexandraki KI; Pizanias M; Uri I; Thomas D; Page T; Kolomodi D; Low CS; Adesanya O; Tsoli M; Gross DJ; Randeva H; Srirajaskanthan R; Grozinsky-Glasberg S; Kaltsas G; Weickert MO
    Endocrine; 2019 Jun; 64(3):690-701. PubMed ID: 30635793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance.
    Scharf M; Petry V; Daniel H; Rinke A; Gress TM
    Neuroendocrinology; 2018; 106(1):30-37. PubMed ID: 28152537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.
    Altieri B; Di Dato C; Martini C; Sciammarella C; Di Sarno A; Colao A; Faggiano A;
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015.
    Genus TSE; Bouvier C; Wong KF; Srirajaskanthan R; Rous BA; Talbot DC; Valle JW; Khan M; Pearce N; Elshafie M; Reed NS; Morgan E; Deas A; White C; Huws D; Ramage J
    Br J Cancer; 2019 Nov; 121(11):966-972. PubMed ID: 31649320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
    Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
    Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
    Enright K; Clemons M; Chow E
    Support Care Cancer; 2004 Jan; 12(1):48-52. PubMed ID: 14577020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).
    Kos-Kudła B; Blicharz-Dorniak J; Handkiewicz-Junak D; Jarząb B; Jarząb M; Kunikowska J; Kuśnierz K; Król R; Królicki L; Krzakowski M; Nasierowska-Guttmejer A; Nowakowska-Duława E; Patkowski W; Szawłowski AW; ;
    Endokrynol Pol; 2013; 64(6):418-43. PubMed ID: 24431116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014.
    Trikalinos NA; Tan BR; Amin M; Liu J; Govindan R; Morgensztern D
    BMC Endocr Disord; 2020 Apr; 20(1):44. PubMed ID: 32245472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration].
    Begum N; Hubold C; Buchmann I; Thorns C; Bouchard R; Lubienski A; Schlöricke E; Zimmermann M; Lehnert H; Bruch HP; Bürk CG
    Zentralbl Chir; 2014 Jun; 139(3):284-91. PubMed ID: 23508839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance.
    Daskalakis K; Tsoli M; Srirajaskanthan R; Chatzellis E; Alexandraki K; Angelousi A; Pizanias M; Randeva H; Kaltsas G; Weickert MO
    Neuroendocrinology; 2019; 108(4):308-316. PubMed ID: 30673674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study.
    Zhang P; Wang W; Lu M; Zeng C; Chen J; Li E; Tan H; Wang W; Yu X; Tang Q; Zhao J; Shen L; Li J
    Cancer Med; 2018 Sep; 7(9):4361-4370. PubMed ID: 30062861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.